Katie Insogna > DLA Piper LLP (US) > Boston, United States > Lawyer Profile
DLA Piper LLP (US) Offices

33 ARCH STREET
26TH FLOOR
BOSTON MA 02110-1447
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Katie Insogna

Work Department
Litigation, Arbitration and Investigations
Position
Partner; Co-Chair, Pharmaceutical and Medical Device Product Liability Sub-practice Group
Career
Katie Insogna’s practice focuses on the defense of pharmaceutical, life science and medical device companies in a variety of cases, including multidistrict product liability litigation and complex commercial litigation.
Katie has extensive expertise with fact and expert witness development, discovery and dispositive motion practice, and trial preparation. Katie has taken and defended numerous party and third-party witness depositions in product liability and commercial litigation cases. She also has argued motions in state and federal courts.
Education
J.D., University of Southern California Gould School of Law; B.A., Georgetown University
Lawyer Rankings
United States > Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
(Next Generation Partners)The ‘extremely responsive and thoughtful’ team at DLA Piper LLP (US) provides an ‘excellent client service and medical device knowledge’ to a wide range of pharmaceuticals companies, including Sanofi and Bayer, across a range of major product liability mandates. While the firm has a growing profile in trying cases, it is particularly adept at achieving an early conclusion of cases, through its effective use of dispositive pre-emption motions and Daubert challenges. Loren Brown in New York regularly acts as national co-ordinating counsel and lead trial counsel in mass torts and MDLs throughout the country, as well as in the context of global litigation – including her work for Bayer in mass tort litigation involving Essure. Based out of Atlanta, product liability chair Christopher Campbell is noted for his high-level strategic advice to manufacturers across a range of products, including many within the pharmaceutical space, where he is appreciated for his ‘guidance on the big picture’, as well his aptitude at handling cross-border mandates. Boston-based global co-chair of the firm’s life sciences sector, Matthew Holian is ‘super smart and very strategic‘ throughout the product life cycle, from risk assessment, pre-litigation discovery, bellwether trials and, ultimately, resolution. ‘Highly-skilled‘ Boston-based Katie Insogna excels at handling high-stakes litigation and counselling. Based out New York, Lucas Przymusinski provides ‘thoughtful guidance‘ to pharma companies across an array of regulatory and litigation matters, including product liability disputes, where his medical and science background provides additional benefit.
United States > Healthcare > Life sciences
(Next Generation Partners)Clients praise DLA Piper LLP (US)‘s litigation offering, nothing that its ‘expert testimony is second to none.’ Product liability cases make up the majority of the team’s high profile work, including advising Sanofi, Bayer, and Novo Nordisk in state and federal court. It also advises pharmaceutical companies on consumer class actions. Commercially, the team acts on a transaction’s full life cycle, encompassing due diligence, company formation, and regulatory issues. Financing is another area of expertise, both via private placements and capital markets offerings. Matthew Holian and Andrew Gilbert co-chair the team from Boston and New Jersey respectively. New York-based Loren Brown heads the litigation practice, with extensive experience on mass torts cases. Baltimore-based Howard Schwartz acts on financings, and Boston-based Katie Insogna acts on product liability matters.
Lawyer Rankings
- Next Generation Partners - United States > Healthcare > Life sciences
- Next Generation Partners - United States > Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Product liability, mass tort and class action - defense: pharmaceuticals and medical devices - United States > Dispute resolution
- Life sciences - United States > Healthcare
Top Tier Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Real estate > Land use/zoning
- Dispute resolution > International litigation
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Media, technology and telecoms > Outsourcing
- Intellectual property > Patents: licensing
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Media, technology and telecoms > Advertising and marketing: transactional and regulatory
- Industry focus > Cannabis
- Antitrust > Cartel
- Dispute resolution > E-discovery
- Tax > Financial products
- Media, technology and telecoms > Fintech
- Tax > International tax
- Intellectual property > Patents: litigation (International Trade Commission)
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Structured finance: securitization
- Media, technology and telecoms > Technology transactions
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Tax > US taxes: contentious
- Labor and employment > Workplace and employment counseling
- Insurance > Advice to insurers
- Insurance > Insurance: non-contentious
- Labor and employment > Labor and employment disputes (including collective actions): defense
- Labor and employment > Labor-management relations
- Healthcare > Life sciences
- Intellectual property > Patents: litigation (full coverage)
- Dispute resolution > Product liability, mass tort and class action - defense: automotive/transport
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Dispute resolution > Securities litigation: defense
- Healthcare > Service providers
- Intellectual property > Trademarks: litigation
- Tax > US taxes: non-contentious
- Finance > Capital markets: equity offerings
- Antitrust > Civil litigation/class actions: defense
- Real estate > Construction (including construction litigation)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > General commercial disputes
- Dispute resolution > M&A litigation: defense
- Media, technology and telecoms > Media and entertainment: litigation
- Media, technology and telecoms > Media and entertainment: transactional
- M&A/corporate and commercial > Private equity buyouts
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Project finance